Skip to content

Agios Pharmaceuticals

US · AGIO #2841 by market cap Listed 1970
27.60 -1.16 -4.03%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:30

✦ Quant Ownership Signal how this is computed

Accumulating
  • The number of reporting institutions increased by 10 in the most recent period (2026/Q3).
  • Total institutional ownership rose 5.0 percentage points.

Ownership vs. money flow

Aligned

Institutions added shares last reporting period, and the stock has seen net inflows in main-fund flow over the last 20 trading sessions - the two line up.

Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.

Institutional ownership

Held by institutions
117.18% +4.99pp
Institutions
295 +10
As of
2026/Q3 vs. prior period

Holder types

Mutual Fund67.72%
Hedge Fund34.00%
Public Company8.36%
Private Company4.41%
VC/PE Fund1.31%
Individual/Insider1.11%
Insurance Company0.93%
Government Pension Fund0.43%

Top holders as of 2026-09-30

BlackRock 10.42% · 6.23M sh
Farallon Capital Management, L.L.C. 9.89% · 5.92M sh
Morgan Stanley 5.75% · 3.44M sh
Lynx1 Capital Management LP 5.70% · 3.41M sh
State Street Global Advisors 5.46% · 3.26M sh
D. E. Shaw & Co., L.P. 5.19% · 3.11M sh
Vanguard Portfolio Management, LLC 4.77% · 2.85M sh
Vanguard Capital Management, LLC 4.49% · 2.69M sh
Armistice Capital LLC 4.01% · 2.40M sh
Erste Asset Management GmbH 3.61% · 2.15M sh
Macquarie Investment Management Business Trust 3.53% · 2.11M sh

Bar length is relative to the largest holder shown here, not to 100% of the company.

Insiders

50 filings tracked · 37 buys · 13 sells

NameRoleStake
Brian Goff Chief Executive Officer 0.31%
Jacqualyn Fouse Chair of the Board of Directors 0.26%
Cecilia Jones Chief Financial Officer 0.09%
Sarah Gheuens Chief Medical Officer and Head of Research & Development 0.09%
James Burns Chief Legal Officer 0.08%
Tsveta Milanova Chief Commercial Officer 0.08%
David Scadden Independent Director 0.03%
Maykin Ho Independent Director 0.03%
Cynthia Smith Independent Director 0.03%
Rahul Ballal Independent Director 0.03%

Insider transactions most recent Form 4 filings

DateNameRoleTypeSharesPrice
2026-10-25 Sarah Gheuens Chief Medical Officer and Head of Research & Development Intent to Sell (Form 144) -7,866 $37.69
2026-10-25 Sarah Gheuens Chief Medical Officer and Head of Research & Development Derivative Exercise and Sale -7,866 $25.01–37.69
2026-10-21 Sarah Gheuens Chief Medical Officer and Head of Research & Development Derivative Exercise and Sale -1,989 $25.01–37.53
2026-10-21 Sarah Gheuens Chief Medical Officer and Head of Research & Development Intent to Sell (Form 144) -500 $37.52
2026-10-20 Sarah Gheuens Chief Medical Officer and Head of Research & Development Intent to Sell (Form 144) -1,489 $37.53
2026-08-03 Sarah Gheuens Chief Medical Officer and Head of Research & Development Automatic Disposition -30,000 $30.48
2026-07-07 Jay Backstrom Independent Director Other Acquisition +1,447 --
2026-06-30 Sarah Gheuens Chief Medical Officer and Head of Research & Development Derivative Exercise and Sale -4,007 $37.56
2026-06-30 Sarah Gheuens Chief Medical Officer and Head of Research & Development Derivative Exercise and Retained +4,368 --
2026-06-17 Jacqualyn Fouse Chair of the Board of Directors Other Derivative Acquisition +2,927 --
2026-06-17 Jacqualyn Fouse Chair of the Board of Directors Other Derivative Acquisition +14,950 $34.16
2026-06-17 Jacqualyn Fouse Chair of the Board of Directors Derivative Exercise and Retained +2,816 --
2026-06-17 Jeffrey Capello Independent Director Other Derivative Acquisition +2,927 --
2026-06-17 Jeffrey Capello Independent Director Other Derivative Acquisition +14,950 $34.16
2026-06-17 Jeffrey Capello Independent Director Derivative Exercise and Retained +2,816 --
2026-06-17 Kaye Foster-Cheek Lead Independent Director Other Derivative Acquisition +2,927 --
2026-06-17 Kaye Foster-Cheek Lead Independent Director Other Derivative Acquisition +14,950 $34.16
2026-06-17 Kaye Foster-Cheek Lead Independent Director Derivative Exercise and Retained +2,816 --
2026-06-17 Jay Backstrom Independent Director Other Derivative Acquisition +2,927 --
2026-06-17 Jay Backstrom Independent Director Other Derivative Acquisition +14,950 $34.16

Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.

Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.

Agios Pharmaceuticals discussion 0 comments

Add a comment